The Cure Parkinson's Trust today welcomed the announcement:

"Seven of the world’s largest pharmaceutical companies have signed up to a groundbreaking consortium aimed at accelerating the development of safe and effective therapies for Parkinson’s."

The Critical Path for Parkinson’s consortium will bring together leading academics; industry members AbbVie, AstraZeneca, Biogen, Eli Lilly and Company, Merck Sharp and Dohme (known as Merck & Co. Inc. in the United States and Canada), Pfizer, and UCB; and founders the Critical Path Institute (C-Path) and Parkinson’s UK, to share data, expertise and resources to promote and develop new treatments for Parkinson’s.

The consortium, which was launched in October 2015, was formed by Parkinson’s UK and C-Path to increase investment into research and development of new Parkinson’s treatments.

The Cure Parkinson's Trust are pleased to be supporting and signing up as a non-paying member of this consortium.

Read the full article here.